Search Results

Advanced Associate Council – Jul 11, 2023

FDA Fully Approves Leqembi for Alzheimers; CMS Unclear on PET Reimbursement – Jul 10, 2023
The FDA has granted full approval to Leqembi (lecanemab); however, CMS has not committed to reimbursement of the needed PET scans.

Dipyridamole Shortage in Canada – Jul 7, 2023
Due to production delays, dypyridamole is currently in short supply in Canada. This shortage poses a significant challenge to healthcare providers across the country, potentially impacting patient care and treatment outcomes.

Pacific Northwest Chapter – Jul 6, 2023
The Pacific Northwest Chapter of SNMMI

Northern California Chapter – Jul 6, 2023
The Northern California Chapter of SNMMI

Central Chapter – Jul 6, 2023
The Central Chapter of SNMMI

SNMMI Keeps Eye on the Patient at 2023 Annual Meeting – Jun 28, 2023
SNMMI hosted nearly 8,000 physicians, technologists, pharmacists, laboratory professionals, scientists and others at its 2023 Annual Meeting, themed Eye on the Patient, held in Chicago, Illinois.

Novel Radiotracer Demonstrates High Diagnostic Efficacy for Obese Patients with Coronary Artery Disease – Jun 27, 2023
A novel PET perfusion radiotracer, F-18 flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to Tc-99m SPECT myocardial perfusion imaging, according to research presented at the 2023 SNMMI Annual Meeting.

Personalized Dosing in Prostate Cancer Treatment Improves Patient Outcomes – Jun 27, 2023
By monitoring early-response biomarkers in men undergoing 177Lu-PSMA prostate cancer treatment, physicians can personalize dosing intervals, significantly improving patient outcomes.

Novel Theranostic Agent Targets Multiple Cancer Types – Jun 27, 2023
A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake, sustained tumor retention, and high contrast in preclinical models, making it a prime candidate for a novel theranostics approach.

Refine by Audience: